SCHEMBL8244207

SCHEMBL8244207

CC(=O)ON1C(=O)c2cccnc2C1=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.48
KDM4E B2RXH2 2/20 0.48
ALDH1A1 P00352 4/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
HPGD P15428 1/20 0.47
TP53 P04637 1/20 0.47
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
HTT P42858 1/20 0.43
HSD17B10 Q99714 1/20 0.43
TDP2 O95551 1/20 0.43
NSD2 O96028 1/20 0.43
ABL1 P00519 1/20 0.43
PLCG1 P19174 1/20 0.43
CES1 P23141 1/20 0.43
PAX8 Q06710 1/20 0.43
RIN1 Q13671 1/20 0.43
THRB P10828 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12088045 0.83 SMN1; SMN2 (0.45) SMN1; SMN2KDM4EALDH1A1L3MBTL1HPGD
SCHEMBL12091766 0.83 CYP2D6 (0.49) SMN1; SMN2KDM4EALDH1A1L3MBTL1HPGD
SCHEMBL859822 0.81 ALDH1A1 (0.47) KDM4EALDH1A1HPGDCYP2C9MEN1
SCHEMBL29838651 0.81 ALDH1A1 (0.47) KDM4EALDH1A1HPGDCYP2C9MEN1
SCHEMBL13495402 0.80 CYP2D6 (0.50) SMN1; SMN2KDM4EALDH1A1L3MBTL1HPGD
SCHEMBL2959934 0.73 ALDH1A1 (0.64) KDM4EALDH1A1L3MBTL1HPGDMEN1
SCHEMBL5865397 0.73 NPC1 (0.50) SMN1; SMN2KDM4EALDH1A1L3MBTL1HPGD
SCHEMBL5031312 0.72 MEN1 (0.52) SMN1; SMN2KDM4EALDH1A1L3MBTL1TP53
SCHEMBL30447750 0.72 MEN1 (0.52) SMN1; SMN2KDM4EALDH1A1L3MBTL1TP53
SCHEMBL12879746 0.72 ALDH1A1 (0.54) SMN1; SMN2KDM4EALDH1A1L3MBTL1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4183773-A1 ZWITTERIONIC REAGENTS Siemens Healthcare Diagnostics Inc. (US) 2023-05-24 EP disclosed
US-9575062-B2 Zwitterion-containing acridinium compounds SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) 2017-02-21 US disclosed
US-9487480-B2 Zwitterionic reagents SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) 2016-11-08 US disclosed
US-20160274094-A1 ZWITTERIONIC REAGENTS SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) 2016-09-22 US disclosed
US-9353056-B2 2016-05-31 US disclosed
US-20140295575-A1 ZWITTERION-CONTAINING ACRIDINIUM COMPOUNDS SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) 2014-10-02 US disclosed
EP-1946108-B1 HIGH QUANTUM YIELD ACRIDINIUM COMPOUNDS AND THEIR USES IN IMPROVING ASSAY SENSITIVITY SIEMENS HEALTHCARE DIAGNOSTICS (US) 2014-10-01 EP disclosed
US-8778624-B2 Zwitterion-containing acridinium compounds SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) 2014-07-15 US disclosed
EP-2074101-B1 STABLE ACRIDINIUM ESTERS WITH FAST LIGHT EMISSION SIEMENS HEALTHCARE DIAGNOSTICS (US) 2012-08-08 EP disclosed
US-8119422-B2 Stable acridinium esters with fast light emission SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) 2012-02-21 US disclosed
US-20100099077-A1 STABLE ACRIDINIUM ESTERS WITH FAST LIGHT EMISSION SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) 2010-04-22 US disclosed
US-20100099077-A1 STABLE ACRIDINIUM ESTERS WITH FAST LIGHT EMISSION SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) 2010-04-22 US disclosed
US-20090162290-A1 METHOD FOR THE SYNTHESIS OF PENTA-PENDANT ENANTIOMER-PURE CHELATORS AND PROCESS FOR THERAPEUTICALLY ACTIVE BIOCONJUGATES PREPARATION BY A COVALENT BINDING THEREOF THERAPHARM GMBH 2009-06-25 US disclosed
US-20090162290-A1 METHOD FOR THE SYNTHESIS OF PENTA-PENDANT ENANTIOMER-PURE CHELATORS AND PROCESS FOR THERAPEUTICALLY ACTIVE BIOCONJUGATES PREPARATION BY A COVALENT BINDING THEREOF THERAPHARM GMBH 2009-06-25 US disclosed
WO-2008067055-A2 STABLE ACRIDINIUM ESTERS WITH FAST LIGHT EMISSION SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) 2008-06-05 WO disclosed
US-20080014660-A1 High Quantum Yield Acridinium Compounds and Their Uses in Improving Assay Sensitivity BAYER HEALTHCARE LLC 2008-01-17 US disclosed
US-20080014660-A1 High Quantum Yield Acridinium Compounds and Their Uses in Improving Assay Sensitivity BAYER HEALTHCARE LLC 2008-01-17 US disclosed
US-7309615-B2 High quantum yield acridinium compounds and their uses in improving assay sensitivity SIEMENS MEDICAL SOLUTIONS DIAGNOSTIC (US) 2007-12-18 US disclosed
US-7309615-B2 High quantum yield acridinium compounds and their uses in improving assay sensitivity SIEMENS MEDICAL SOLUTIONS DIAGNOSTIC (US) 2007-12-18 US disclosed
WO-2007028639-A1 METHOD FOR THE SYNTHESIS OF PENTAPENDANT ENANTIOMER-PURE CHELATORS AND PROCESS FOR THERAPEUTICALLY ACTIVE BIO-CONJUGATES PREPARATION BY A COVALENT BINDING OF THEREOF THERAPHARM GMBH (CH) 2007-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090162290-A1 METHOD FOR THE SYNTHESIS OF PENTA-PENDANT ENANTIOMER-PURE CHELATORS AND PROCESS FOR THERAPEUTICALLY ACTIVE BIOCONJUGATES PREPARATION BY A COVALENT BINDING THEREOF C5, C3AR1, SPR SMN1; SMN2 3717/4885KDM4E 1051/4885ALDH1A1 733/4885
US-20100099077-A1 STABLE ACRIDINIUM ESTERS WITH FAST LIGHT EMISSION ACR, NAALAD2, CES2 SMN1; SMN2 4028/4885KDM4E 3772/4885ALDH1A1 319/4885
US-20160274094-A1 ZWITTERIONIC REAGENTS BTD, HLCS, WIZ SMN1; SMN2 4676/4885KDM4E 3592/4885ALDH1A1 4381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.